Phase 3 Trial Designs Evaluating Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy (P10-11.027)
To present two Phase 3 trial designs which will evaluate riliprubart in 1) people with chronic inflammatory demyelinating polyneuropathy (CIDP) who experienced an inadequate response or failure to at least one line of treatment (Standard-of-care [SOC]-refractory) and 2) responders to IVIg with residual disability despite maintenance SOC treatment.
Authors
- Richard A. Lewis (ORCID: https://orcid.org/0000-0001-5475-3890)
- Claudia Sommer (ORCID: https://orcid.org/0000-0002-7064-5002)
- Luís Querol (ORCID: https://orcid.org/0000-0002-4289-8264)
- Miguel Alonso‐Alonso (ORCID: https://orcid.org/0000-0003-3372-9933)
- Erik Wallstroem
- Pieter A. van Doorn (ORCID: https://orcid.org/0000-0003-2584-3357)
- Nazem Atassi (ORCID: https://orcid.org/0000-0002-1856-2330)
- Jeffrey A. Allen (ORCID: https://orcid.org/0000-0001-8753-2680)
- Xiaodong Luo (ORCID: https://orcid.org/0000-0002-8214-9874)
- Ingemar S.J. Merkies
Institutions
- Cedars-Sinai Medical Center (US)
- University of Minnesota (US)
- Hospital de Sant Pau (ES)
- Erasmus MC (NL)
- Maastricht University (NL)
- AVEO Oncology (United States) (US)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Sanofi (United States) (US)
- Centro de Investigación Biomédica en Red (ES)
- University of Curaçao (CW)
- Universitätsklinikum Würzburg (DE)
- Klinik und Poliklinik für Neurologie (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208529
- Citations
- 2
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.78